MSB 10.4% $1.49 mesoblast limited

Athersys’, Pluristem’s and Mesoblast’s mesenchymal stromal cell therapies vie for efficacy in Covid-19, page-55

  1. 2,683 Posts.
    lightbulb Created with Sketch. 187
    yes I was holding few days ago, but exited due to technical breakdown and was trying to understand why share price lost momentum
    did some more research and now I can see why
    so will keep watching and re-enter at cheaper entry point
    been watching MSB for years... along with other stem cell hopefuls

    apologies if this appears to be hostile, but I can see a lot of emotional holders on this forum are quick to defend, etc, which is understandable, it's been a long journey

    it just seems current market valuation might be on the high side
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.